The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
ApexOnco Front Page
Recent articles
The company advances the IDRX-originated KIT inhibitor GSK6042981 into pivotal trials.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
But more detail is awaited, especially on toxicity.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
The ESMO regular abstract lift reveals first human datasets for several projects.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
